PL3297653T3 - Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1 - Google Patents

Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1

Info

Publication number
PL3297653T3
PL3297653T3 PL16800620T PL16800620T PL3297653T3 PL 3297653 T3 PL3297653 T3 PL 3297653T3 PL 16800620 T PL16800620 T PL 16800620T PL 16800620 T PL16800620 T PL 16800620T PL 3297653 T3 PL3297653 T3 PL 3297653T3
Authority
PL
Poland
Prior art keywords
glp
antagonists
post
treatment
bariatric hypoglycemia
Prior art date
Application number
PL16800620T
Other languages
English (en)
Inventor
Tracey L. MCLAUGHLIN
Colleen M. CRAIG
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of PL3297653T3 publication Critical patent/PL3297653T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL16800620T 2015-05-22 2016-05-23 Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1 PL3297653T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562165743P 2015-05-22 2015-05-22
US201562254175P 2015-11-11 2015-11-11
US201662329850P 2016-04-29 2016-04-29
PCT/US2016/033836 WO2016191394A1 (en) 2015-05-22 2016-05-23 Treatment of post-bariatric hypoglycemia with glp-1 antagonists
EP16800620.3A EP3297653B1 (en) 2015-05-22 2016-05-23 Treatment of post-bariatric hypoglycemia with glp-1 antagonists

Publications (1)

Publication Number Publication Date
PL3297653T3 true PL3297653T3 (pl) 2022-01-31

Family

ID=57393681

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16800620T PL3297653T3 (pl) 2015-05-22 2016-05-23 Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1
PL16800621T PL3297654T3 (pl) 2015-05-22 2016-05-23 Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16800621T PL3297654T3 (pl) 2015-05-22 2016-05-23 Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)

Country Status (18)

Country Link
US (10) US10639354B2 (pl)
EP (4) EP3297654B1 (pl)
AU (6) AU2016267057B2 (pl)
BR (2) BR112017025000A2 (pl)
CA (2) CA3024353A1 (pl)
CL (2) CL2017002911A1 (pl)
CY (2) CY1124616T1 (pl)
DK (2) DK3297653T3 (pl)
ES (2) ES2897955T3 (pl)
HR (2) HRP20211768T1 (pl)
HU (2) HUE055728T2 (pl)
LT (2) LT3297654T (pl)
PL (2) PL3297653T3 (pl)
PT (2) PT3297653T (pl)
RS (2) RS62368B1 (pl)
SI (2) SI3297654T1 (pl)
SM (2) SMT202100668T1 (pl)
WO (2) WO2016191394A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2818181B1 (en) 2007-01-08 2018-10-24 The Trustees Of The University Of Pennsylvania Compositions and medical uses thereof
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
RS62368B1 (sr) 2015-05-22 2021-10-29 Univ Leland Stanford Junior Lečenje postbarijatrijske hipoglikemije eksendinom(9-39)
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
BR112019010236A2 (pt) * 2016-11-21 2019-08-20 Eiger Biopharmaceuticals, Inc formulações tamponadas de exendina (9-39)
BR112020014719A2 (pt) * 2018-01-23 2020-12-08 Xeris Pharmaceuticals, Inc. Tratamento de hipoglicemia pós-bariátrica usando glucagon estável em minidose
GB201816639D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist
CA3115527A1 (en) * 2018-10-15 2020-04-23 Eiger Biopharmaceuticals, Inc. Avexitide for the treatment of hyperinsulinemic hypoglycemia
WO2020144378A1 (en) * 2019-01-11 2020-07-16 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) * 2022-08-21 2024-02-29 M. Arkin (1999) Ltd Glp-1 receptor antagonist and methods of use thereof
CN121219002A (zh) * 2023-04-21 2025-12-26 小利兰斯坦福大学董事会 Glp-1r拮抗作用改善胃肠外科手术后的营养
WO2025235995A1 (en) * 2024-05-10 2025-11-13 The Board Of Trustees Of The Leland Stanford Junior University Use of glp-1 receptor agonists alone or in combination with other gastrointestinal hormones that delay gastric emptying for treatment of postbariatric hypoglycemia

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9306551A (pt) 1992-06-15 1998-09-15 Pfizer Derivados de peptídeo do tipo glucagona e de insulinotropina
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
ES2359031T3 (es) 1996-08-08 2011-05-17 Amylin Pharmaceuticals, Inc. Composición farmacéutica que comprende un péptido de exendina-4.
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
JP3270761B2 (ja) 1998-01-30 2002-04-02 ノボ ノルディスク アクティーゼルスカブ 注射器
ES2233089T3 (es) 1998-12-10 2005-06-01 Agouron Pharmaceuticals, Inc. Antagonistas no peptidos del receptor de glp-1 y metodos de uso.
EP1140145B2 (en) 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Novel exendin agonist formulations and methods of administration thereof
DE60032331T2 (de) 1999-01-14 2007-06-21 Amylin Pharmaceuticals, Inc., San Diego Exendine zur glucagon suppression
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
AU2002257132A1 (en) 2001-04-06 2002-10-21 The Trustees Of The University Of Pennsylvania Erbb interface peptidomimetics and methods of use thereof
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
EP1609479A4 (en) 2003-03-13 2010-01-20 Mitsubishi Tanabe Pharma Corp Tumorigenesis INHIBITOR
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005110425A1 (en) 2004-04-15 2005-11-24 Alkermes, Inc. Polymer-based sustained release device
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
DK1888031T3 (da) 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
DK1971362T3 (en) 2005-08-19 2015-01-26 Amylin Pharmaceuticals Llc Exendin for treating diabetes and reducing body weight
US8945564B2 (en) 2006-04-21 2015-02-03 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
KR20090031368A (ko) 2006-05-26 2009-03-25 아밀린 파마슈티칼스, 인크. 울혈성 심부전 치료용 조성물 및 방법
EP2818181B1 (en) * 2007-01-08 2018-10-24 The Trustees Of The University Of Pennsylvania Compositions and medical uses thereof
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
PL2144649T3 (pl) 2007-04-05 2012-01-31 Tecpharma Licensing Ag Aplikator wyposażony w człon napędowy z funkcją sterującą
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
CN105903005A (zh) 2008-05-05 2016-08-31 奥拉姆德有限公司 用于口服给予艾塞那肽的方法和组合物
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
DK2310042T3 (da) 2008-07-08 2013-03-04 Novartis Ag Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi
EP2341905B2 (en) 2008-09-04 2023-09-13 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
BRPI1014065A2 (pt) 2009-04-03 2016-04-12 Nestec Sa melhora na promoção do crescimento compensatório saudável
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013059323A1 (en) 2011-10-18 2013-04-25 Prolynx Llc Peg conjugates of exenatide
WO2013120022A2 (en) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
RU2644214C2 (ru) 2012-03-26 2018-02-08 Санофи СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RS62368B1 (sr) 2015-05-22 2021-10-29 Univ Leland Stanford Junior Lečenje postbarijatrijske hipoglikemije eksendinom(9-39)
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
BR112019010236A2 (pt) 2016-11-21 2019-08-20 Eiger Biopharmaceuticals, Inc formulações tamponadas de exendina (9-39)
WO2024030934A2 (en) 2022-08-05 2024-02-08 Indiana University Research And Technology Corporation Glucagon-like peptide-1 receptor antagonists

Also Published As

Publication number Publication date
EP3297653A1 (en) 2018-03-28
ES2887723T3 (es) 2021-12-27
HUE055728T2 (hu) 2021-12-28
WO2016191395A1 (en) 2016-12-01
RS62627B1 (sr) 2021-12-31
US12220444B2 (en) 2025-02-11
AU2016267057B2 (en) 2021-12-23
US20200276271A1 (en) 2020-09-03
PT3297654T (pt) 2021-09-06
US20210290731A1 (en) 2021-09-23
US10639354B2 (en) 2020-05-05
CA3024353A1 (en) 2016-12-01
US20210315974A1 (en) 2021-10-14
BR112017024997A2 (pt) 2018-07-31
US20230346890A1 (en) 2023-11-02
AU2022202506A1 (en) 2022-05-12
EP3297653B1 (en) 2021-09-15
SMT202100668T1 (it) 2022-01-10
HUE057301T2 (hu) 2022-05-28
EP3936143A1 (en) 2022-01-12
CA3024358A1 (en) 2016-12-01
US11617782B2 (en) 2023-04-04
SMT202100488T1 (it) 2021-11-12
AU2016267057A1 (en) 2017-12-14
DK3297654T3 (da) 2021-09-06
AU2016267052B2 (en) 2022-01-20
PL3297654T3 (pl) 2021-12-20
AU2022201973A1 (en) 2022-04-14
AU2025217292A1 (en) 2025-09-04
SI3297653T1 (sl) 2022-01-31
US20180147261A1 (en) 2018-05-31
US20250255935A1 (en) 2025-08-14
US10993991B2 (en) 2021-05-04
US10660937B2 (en) 2020-05-26
HRP20211285T1 (hr) 2022-01-07
US11622995B2 (en) 2023-04-11
CY1124616T1 (el) 2022-07-22
US20250082730A1 (en) 2025-03-13
AU2022202506B2 (en) 2025-06-05
LT3297654T (lt) 2021-10-25
EP3297654A4 (en) 2018-04-11
CL2017002913A1 (es) 2018-06-01
CY1125147T1 (el) 2023-03-24
WO2016191394A1 (en) 2016-12-01
BR112017025000A2 (pt) 2018-08-07
AU2025220813A1 (en) 2025-09-11
CL2017002911A1 (es) 2018-05-25
US20200276272A1 (en) 2020-09-03
US20180117122A1 (en) 2018-05-03
AU2016267052A1 (en) 2017-12-14
ES2897955T3 (es) 2022-03-03
AU2022201973B2 (en) 2025-05-15
EP3297654A1 (en) 2018-03-28
SI3297654T1 (sl) 2021-11-30
EP3978011A1 (en) 2022-04-06
RS62368B1 (sr) 2021-10-29
LT3297653T (lt) 2022-01-10
EP3297653A4 (en) 2018-12-26
HRP20211768T1 (hr) 2022-02-18
US10993992B2 (en) 2021-05-04
DK3297653T3 (da) 2021-10-18
PT3297653T (pt) 2021-10-25
US12102663B2 (en) 2024-10-01
US20240000894A1 (en) 2024-01-04
EP3297654B1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
HUE057301T2 (hu) Bariátriai eljárást követõ hipoglikémia kezelése GLP-1 antagonistákkal
IL251741A0 (en) Co-agonists for glucagon and 1- glp receptors
PL3368101T3 (pl) Autoiniektor jednorazowego użytku
ZA201802017B (en) Novel insulin analogs and use thereof
IL248856A0 (en) New treatment
ZA201706059B (en) Method of treatment with tradipitant
AU362192S (en) Bath
PL3212258T3 (pl) Strzykawka z chowaną igłą
TWD174559S (zh) 浴缸之部分
IL251013A0 (en) Implantable electrode
PT3188778T (pt) Injetor tipo caneta
ZA201704521B (en) Treatment of ocular conditions using progenitor cells
PL3139948T3 (pl) Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201411027D0 (en) Treatment
GB201412411D0 (en) Treatment
HUE048860T2 (hu) 1-es típusú cukorbetegség kezelése GLP-1 és anti-IL-21 alkalmazásával
GB201513922D0 (en) Treatment of hyperpigmentation
GB201417423D0 (en) Bath
GB201417719D0 (en) New treatment
PH32014000070S1 (en) Injector
GB201413317D0 (en) Atheroscierosis treatment
GB201412410D0 (en) Treatment
GB201408384D0 (en) New treatment
GB201400235D0 (en) Treatment